Compare GEOS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEOS | PLX |
|---|---|---|
| Founded | 1980 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.6M | 204.9M |
| IPO Year | 1997 | 1998 |
| Metric | GEOS | PLX |
|---|---|---|
| Price | $15.18 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 302.0K | ★ 510.9K |
| Earning Date | 02-04-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $110,803,000.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $25.05 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $5.51 | $1.32 |
| 52 Week High | $29.89 | $3.10 |
| Indicator | GEOS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 42.13 |
| Support Level | $14.17 | $1.72 |
| Resistance Level | $15.91 | $1.85 |
| Average True Range (ATR) | 1.29 | 0.09 |
| MACD | 0.40 | 0.02 |
| Stochastic Oscillator | 61.14 | 47.62 |
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.